FDA regulatory timeline
2023 — 202615 EVENTS TRACKEDThe peptide regulatory landscape has shifted dramatically since 2023. This timeline tracks every major FDA action — Category 2 restrictions, warning letters, vendor shutdowns, GLP-1 shortage resolutions, compounding pharmacy deadlines, and the pending RFK Jr. reclassification. Updated as events unfold.
FDA begins Category 2 restrictions on research peptides
The FDA starts moving popular research peptides from Category 1 (compounding permitted) to Category 2 (compounding not permitted due to safety concerns). This marks the beginning of systematic regulatory pressure on the peptide supply chain.
17 peptides placed on Category 2 restricted list
The restricted list grows to include BPC-157, TB-500, GHK-Cu, Ipamorelin, CJC-1295, Selank, Semax, Epithalon, and others. Compounding pharmacies can no longer legally produce these peptides under FDA enforcement discretion.
Category 2 list expands to 19 peptides
Two additional peptides are added to the restricted list. 503A and 503B compounding pharmacies face increasing compliance pressure. Many begin winding down peptide compounding operations.
FDA issues warning letters to peptide vendors
Summit Research Peptides, Prime Peptides, Xcel Peptides, and SwissChems receive FDA warning letters for selling unapproved new drugs. This signals escalation from Category 2 restrictions to active enforcement against the gray market.
FDA determines tirzepatide shortage resolved
The FDA removes tirzepatide from the drug shortage list, closing the legal loophole that allowed compounding pharmacies to produce generic tirzepatide under shortage provisions. Compounders face a wind-down deadline.
FDA ends interim category system for new substances
The FDA announces it will no longer categorize newly nominated bulk drug substances into interim categories. All new substances must complete the full review process before any compounding is permitted. This effectively closes the pipeline for adding new peptides to the legal compounding list.
FDA removes semaglutide from drug shortage list
With the semaglutide shortage officially resolved, compounders lose the legal basis for producing generic semaglutide. 503A pharmacies face an April 22 deadline; 503B facilities face a May 22 deadline to cease GLP-1 compounding.
RFK Jr. announces reclassification of 14 peptides
Robert F. Kennedy Jr., now leading HHS, announces plans to return 14 peptides to Category 1 status, which would restore legal compounding. The list includes BPC-157, TB-500, GHK-Cu, Ipamorelin, CJC-1295, Sermorelin, AOD-9604, and others. As of April 2026, formal FDA reclassification has not been published.
Peptide Sciences shuts down
One of the largest and most established US peptide research chemical suppliers ceases operations. The closure follows escalating FDA enforcement and represents a major supply chain disruption for the research peptide market.
503A pharmacy deadline for GLP-1 compounding
Traditional compounding pharmacies (503A) must cease compounding semaglutide and tirzepatide by this date. Many clinics that relied on compounded GLP-1 agonists for weight management patients lose their supply.
503B facility deadline for GLP-1 compounding
Outsourcing facilities (503B) must cease GLP-1 compounding one month after 503A pharmacies. This closes the last remaining legal pathway for compounded semaglutide and tirzepatide.
FDA raids Amino Asylum warehouse
Federal agents raid Amino Asylum's warehouse operations in Tennessee/Kentucky. The site goes offline immediately and all operations cease. This is one of the first physical law enforcement raids on a peptide vendor, signaling a new level of enforcement intensity.
FDA issues 50+ warning letters to GLP-1 compounders
The FDA sends more than 50 warning letters to US and international compounders and manufacturers of GLP-1 receptor agonists. This mass enforcement action is unprecedented in scope for the peptide industry.
Multiple criminal prosecutions with $1.79M-$3M+ forfeitures
Federal prosecutors secure forfeitures ranging from $1.79 million to over $3 million in cases against peptide vendors. Criminal charges include distribution of unapproved new drugs, conspiracy, and money laundering.
RFK Jr. reclassification still pending formal publication
Despite the February 2025 announcement, no formal FDA rule change has been published returning the 14 announced peptides to Category 1 status. The reclassification remains in administrative limbo. Compounding pharmacies cannot legally resume production until formal rulemaking is completed.
What this means for peptide users
The regulatory environment for peptides has tightened significantly since 2023. The FDA's Category 2 list now restricts compounding of most popular research peptides including BPC-157, TB-500, and several growth hormone secretagogues. Enforcement has escalated from warning letters to physical raids and criminal prosecutions with multi-million dollar forfeitures.
The RFK Jr. reclassification announcement in February 2025 offered hope that 14 peptides would return to legal compounding status, but as of April 2026, no formal FDA rule change has been published. The regulatory outcome remains uncertain.
For current legal status of specific peptides, see individual peptide profiles or the peptide legal status guide.
The regulatory story is still being written. This timeline is a living document, updated as events unfold. Bookmark it — the next chapter may change everything.